A pilot study conducted in Minnesota is pointing to a possible new way for scientists to study medical marijuana without becoming entangled in federal regulatory hurdles that have long limited clinical research in this area.
Researchers worked alongside Minnesota’s state-run medical marijuana program to test whether marijuana could help reduce symptoms in people recently diagnosed with advanced pancreatic cancer.
The findings suggest the approach is safe, practical, and acceptable to patients, while also offering early signs that cannabis may provide symptom relief.
The study focused on individuals with locally metastatic pancreatic adenocarcinoma, a disease often accompanied by intense pain, sleep problems, and loss of appetite. Previous research has shown that marijuana may help ease some of these issues, but strict federal controls have made large, high-quality trials difficult to conduct.
Under current federal law, marijuana is categorized by the DEA as a Schedule 1 drug, which means researchers who handle cannabis must secure special federal licenses. These requirements can be time-consuming and costly, discouraging many academic studies.
To work around those obstacles, the researchers partnered directly with the state’s medical marijuana program. This approach allowed patients to obtain cannabis legally through established channels, while researchers focused on monitoring outcomes rather than managing the drug supply.
The pilot trial enrolled 32 patients, with a median age of 71, and 53% being women. At the start of the study, most participants reported moderate to severe symptoms, including sleep problems (85%), pain (77%), and reduced appetite (69%).
Participants received education on safe marijuana use, emphasizing cautious dosing. They continued standard cancer treatments and supportive medications as needed. Half of the group received immediate access to medical cannabis during the first eight weeks, while the remainder began the intervention later, serving as a comparison group.
Ninety percent reported symptom improvement without negative health effects and said they would recommend medical cannabis to others with similar conditions.
Although differences between the early and delayed groups did not reach statistical significance, patients who received cannabis earlier showed higher rates of improvement in sleep, appetite, and pain by the eight-week mark.
The researchers emphasized caution when interpreting these findings, but said the consistency of patient reports suggests real potential benefits. One participant, interviewed shortly after starting the intervention, described being able to sleep through the night for the first time since diagnosis.
The team has since expanded the protocol to include people with advanced colorectal cancer, with additional enrollment underway. Overall, the results suggest that collaboration with state marijuana programs could help researchers overcome long-standing barriers and generate more rigorous data on medical marijuana use in cancer care.
As more such studies are conducted and they provide additional scientific data on the benefits of using medical marijuana products, more patients could gain confidence in trying products from licensed companies like TerrAscend Corp. (TSX: TSND) (OTCQX: TSNDF) to help in symptom management alongside their conventional medications.
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer
CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is powered by IBN
